This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: July 15th, 2011 - July 15th, 2012

Estimated time to complete activity: 1 hour.

TARGET AUDIENCE
This activity was developed for health-system pharmacists and oncology pharmacists.

LEARNING OBJECTIVES
At the end of this activity, participants will be able to:

• Compare and contrast the primary end points used in pivotal clinical trials for hematologic malignancies
• Determine which end points are the most appropriate and clinically relevant for assessing the efficacy of novel targeted agents for multiple myeloma, chronic myeloid leukemia, and non-Hodgkin lymphoma
• Evaluate surrogate end points as they relate to optimal long-term outcomes for patients with hematologic malignancies
• Analyze the results from clinical trials to assess the justification of incorporating novel targeted agents into standards of care and effective benefit design and utilization management approaches

REGISTERED PHARMACY DESIGNATION

Medical Learning Institute, Inc., is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-11-029-H01-P.

DISCLOSURES
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc., for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Shelly Chun, PharmD, a reviewer for MLI, has nothing to disclose.

Linda Ritter, PhD, Center of Excellence Media, has nothing to disclose.

James T. Kenney Jr., RPh, MBA, has nothing to disclose.

Michael Mauro, MD, receives research grants from Novartis Oncology and Bristol-Myers Squibb.

Gary Yee, PharmD, FCCP, BCOP, has nothing to disclose.

DISCLAIMER
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias toward or promotion for the agent discussed in this program should be inferred.